• Lasa Supergenerics schedules board meeting on May 29, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
• The trading window closure remains in effect until 48 hours after the declaration of the audited financial results.
• The intimation is made pursuant to SEBI Listing Regulations and is available on company and stock exchange websites.